Arwin M. Ridder
Leiden, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial.
Journal: Blood pressure monitoring
Published: March 27, 2018
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
Journal: European urology
Published: January 17, 2018
Cardiovascular Safety of the β3 -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial.
Journal: Journal of clinical pharmacology
Published: November 29, 2017
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
Journal: BJU international
Published: April 19, 2017
Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
Journal: Neurourology and urodynamics
Published: January 20, 2017
Electronic bladder diaries of differing duration versus a paper diary for data collection in overactive bladder.
Journal: Neurourology and urodynamics
Published: January 12, 2015
A clinical perspective on the analysis and presentation of the number of incontinence episodes following treatment for OAB.
Journal: Neurourology and urodynamics
Published: December 04, 2014
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Journal: European urology
Published: December 20, 2013
A phase II dose-ranging study of mirabegron in patients with overactive bladder.
Journal: International urogynecology journal
Published: October 12, 2012
A proof-of-concept study: mirabegron, a new therapy for overactive bladder.
Journal: Neurourology and urodynamics
Published: September 28, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026